Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
- Yasmin Abaza,
- Hagop Kantarjian,
- Guillermo Garcia-Manero,
- Elihu Estey,
- Gautam Borthakur,
- Elias Jabbour
- University of Texas MD Anderson Cancer Center,
- University of Washington,
- University of Medicine and Dentistry of New Jersey,
- University of California at Irvine
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients with newly diagnosed acute promyelocytic leukemia (APL). A recent study demonstrated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients. We examined the long-term outcome of patients with newly diagnosed APL treated at our institution on 3 consecutive prospective clinical trials, using the combination of ATRA and ATO, with or without GO. For induction, all patients received ATRA (45 mg/m<sup>2</sup> daily) and ATO (0.15 mg/kg daily) with a dose of GO (9 mg/m<sup>2</sup> on day 1) added to high-risk patients (white blood cell count, >10 × 10<sup>9</sup>/L), as well as low-risk patients who experienced leukocytosis during induction. Once in complete remission, patients received 4 cycles of ATRA plus ATO consolidation. One hundred eighty-seven patients, including 54 with high-risk and 133 with low-risk disease, have been treated. The complete remission rate was 96% (52 of 54 in high-risk and 127 of 133 in low-risk patients). Induction mortality was 4%, with only 7 relapses. Among low-risk patients, 60 patients (45%) required either GO or idarubicin for leukocytosis. Median duration of follow-up was 47.6 months. The 5-year event-free, disease-free, and overall survival rates are 85%, 96%, and 88%, respectively. Late hematological relapses beyond 1 year occurred in 3 patients. Fourteen deaths occurred beyond 1 year; 12 were related to other causes. This study confirms the durability of responses with this regimen.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 1275-1283 (9 pages)Journal (Volume, Issue Number)
Blood (Volume 129, Issue 10)Publication milestones
- Published - 03/09/2017
Publication status
Published - 03/09/2017
ISSN
0006-4971Publication IDs
- Scopus: 85015251442
- PubMed: 28003274
- ORCID: /0000-0002-8636-1071/work/68811276
Publication metrics
Metrics
Fractional count
1
Fractional count
0.04
Fractional count
27
Fractional count
0.96
Fractional count
1
Fractional count
1
SciVal
citations
113
SciVal
FWCI
7.01
SciVal
Author count
28
SciVal
Paper percentile
99
SciVal
Top percentile
1
PlumX, opens in new tab
Citation count
265
Captures
202
Social media
3
Mentions
2
Funding Details
FunderFunding number
NCI
P30CA016672
